Alkem Laboratories announced the incorporation of a new subsidiary in the Kingdom of Saudi Arabia on November 8, 2026. This move is a strategic step to expand the company’s business operations and market reach into the Middle East. The subsidiary, named ‘Alkem Pharma Company’, will operate as a limited liability company and focus on the manufacture, import, marketing, and distribution of pharmaceuticals and nutraceutical products.
Strategic Expansion into Saudi Arabia
Alkem Laboratories Limited has officially announced the incorporation of its new subsidiary in the Kingdom of Saudi Arabia. The entity, named ‘Alkem Pharma Company’, is a Limited Liability Company and marks a significant step in the company’s international growth strategy. This incorporation was completed on November 8, 2026.
Joint Venture Details
The formation of this subsidiary is in line with the Shareholders’ Agreement previously intimated by the company. It is structured as a joint venture, representing a strategic investment aimed at expanding Alkem’s core business and increasing its market presence within Saudi Arabia. The subsidiary will be involved in the manufacture, import, marketing, and distribution of pharmaceutical and/or nutraceutical products.
Financial and Ownership Structure
The Joint Venture has a capital of 7,500,000.0 SAR, divided into 75,000.0 shares of 100 SAR each. Alkem Laboratories has acquired 51% of the total share capital, subscribing to 38,250 shares for a total consideration of 3,825,000.00 SAR. This acquisition does not fall under related party transactions, and no promoter group companies have any interest in the entity.
Source: BSE
